Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.
Wang J, Rajput A, Kan JL, Rose R, Liu XQ, Kuropatwinski K, Hauser J, Beko A, Dominquez I, Sharratt EA, Brattain L, Levea C, Sun FL, Keane DM, Gibson NW, Brattain MG. Wang J, et al. Among authors: gibson nw. J Biol Chem. 2009 Apr 17;284(16):10912-22. doi: 10.1074/jbc.M809551200. Epub 2009 Feb 18. J Biol Chem. 2009. PMID: 19224914 Free PMC article.
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, O'Connor M, Yao Y, Pirritt C, Buck E, Eyzaguirre A, Arnold LD, Gibson NW, Pachter JA. Ji QS, et al. Among authors: gibson nw. Mol Cancer Ther. 2007 Aug;6(8):2158-67. doi: 10.1158/1535-7163.MCT-07-0070. Epub 2007 Aug 1. Mol Cancer Ther. 2007. PMID: 17671083
Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ, Pachter JA. Bhagwat SV, et al. Among authors: gibson nw. Mol Cancer Ther. 2011 Aug;10(8):1394-406. doi: 10.1158/1535-7163.MCT-10-1099. Epub 2011 Jun 14. Mol Cancer Ther. 2011. PMID: 21673091
Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).
Mulvihill MJ, Kan JL, Beck P, Bittner M, Cesario C, Cooke A, Keane DM, Nigro AI, Nillson C, Smith V, Srebernak M, Sun FL, Vrkljan M, Winski SL, Castelhano AL, Emerson D, Gibson N. Mulvihill MJ, et al. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1669-73. doi: 10.1016/j.bmcl.2005.01.044. Bioorg Med Chem Lett. 2005. PMID: 15745819
3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
Mulvihill MJ, Kan JL, Cooke A, Bhagwat S, Beck P, Bittner M, Cesario C, Keane D, Lazarescu V, Nigro A, Nillson C, Panicker B, Smith V, Srebernak M, Sun FL, O'Connor M, Russo S, Fischetti G, Vrkljan M, Winski S, Castelhano AL, Emerson D, Gibson NW. Mulvihill MJ, et al. Among authors: gibson nw. Bioorg Med Chem Lett. 2006 May 15;16(10):2729-33. doi: 10.1016/j.bmcl.2006.02.020. Epub 2006 Feb 28. Bioorg Med Chem Lett. 2006. PMID: 16504501
99 results